TLR3 and colorectal carcinoma: This study reveals that AV drug-induced gut virome dysbiosis impairs the TLR3-IRF3-IFN-β pathway, reducing the numbers of immune cells, such as DCs and CD8+ T cells, which are crucial for an effective antitumor response in CRC.